SAB Biotherapeutics Inc (SABS) - Total Assets
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) holds total assets worth $238.21 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SAB Biotherapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how SAB Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see SABS stock market capitalisation for the company's overall valuation and market capitalisation.
SAB Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
SAB Biotherapeutics Inc's total assets of $238.21 Million consist of 58.5% current assets and 41.5% non-current assets. Review how much debt does SAB Biotherapeutics Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.1% |
| Accounts Receivable | $946.78K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how SAB Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SABS stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SAB Biotherapeutics Inc's current assets represent 58.5% of total assets in 2025, an increase from 51.6% in 2019.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2025, down from 35.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
SAB Biotherapeutics Inc Competitors by Total Assets
Key competitors of SAB Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
SAB Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.22 | 0.87 | 2.09 |
| Quick Ratio | 9.22 | 0.87 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $96.23 Million | $-1.37 Million | $11.44 Million |
SAB Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between SAB Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.45 |
| Latest Market Cap to Assets Ratio | 1.85 |
| Asset Growth Rate (YoY) | 291.0% |
| Total Assets | $172.81 Million |
| Market Capitalization | $319.36 Million USD |
Valuation Analysis
Above Book Valuation: The market values SAB Biotherapeutics Inc's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: SAB Biotherapeutics Inc's assets grew by 291.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual total assets of SAB Biotherapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $172.81 Million | +291.01% |
| 2024-12-31 | $44.20 Million | -47.35% |
| 2023-12-31 | $83.94 Million | +64.90% |
| 2022-12-31 | $50.90 Million | -37.26% |
| 2021-12-31 | $81.14 Million | +43.52% |
| 2020-12-31 | $56.54 Million | +214.04% |
| 2019-12-31 | $18.00 Million | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more